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OBJECTIVE — Thisstudyaimedtoinvestigatetheprevalenceandriskfactorsassociatedwith
sexual dysfunction in a well-characterized cohort of women with type 1 diabetes.
RESEARCH DESIGN AND METHODS — The study was conducted in women en-
rolled in the long-term Epidemiology of Diabetes Interventions and Complications (EDIC)
study,aNorthAmericanstudyofmenandwomenwithtype1diabetes.Atyear10oftheEDICstudy,
652 female participants were invited to complete a validated self-report measure of sexual function,
standardized history and physical examinations, laboratory testing, and mood assessment.
RESULTS — Of the sexually active women with type 1 diabetes in the EDIC study, 35% met
criteria for female sexual dysfunction (FSD). Women with FSD reported loss of libido (57%);
problemswithorgasm(51%),lubrication(47%),andarousal(38%);andpain(21%).Univariate
analyses revealed a positive association between FSD and age (P  0.0041), marital status (P 
0.0016), menopausal status (P  0.0019), microvasculopathy (P  0.0092), and depression
(P  0.0022). However, in a multivariate analysis, only depression (P  0.004) and marital
status (P  0.003) were signiﬁcant predictors of FSD.
CONCLUSIONS — FSD is common in women with type 1 diabetes and affects all aspects of
sexual function and satisfaction. Depression is the major predictor of sexual dysfunction in women
with type 1 diabetes. These ﬁndings suggest that women with type 1 diabetes should be routinely
queried about the presence of sexual dysfunction and possible co-association with depression.
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D
iabetes has long been considered a
major cause of impaired sexual
function. Both men with type 1 and
type 2 diabetes have been shown to have
substantially increased risk of erectile
dysfunction (ED) (1–5). Beyond the ef-
fects of comorbidities, such as older age,
use of antihypertensive medication, high
BMI, and smoking, the severity and dura-
tion of diabetes and its vascular and neu-
rological complications, which cause
abnormalitiesintheendotheliumornitric
oxide–related mechanisms in the corpora
cavernosa,havebeenstronglylinkedwith
the development of sexual dysfunction in
men (1,4,5).
Women with diabetes have similar
rates of cardiovascular and neurological
complications, and therefore similar rates
of sexual dysfunction might be antici-
pated. Sexual functioning of women with
diabetes, however, has received far less
attention in research, and results are less
conclusive than those of studies in men
(6). In general, studies of sexual dysfunc-
tion in women have lagged behind those
in men, likely due to several factors, in-
cluding a lack of standardized deﬁnitions
of sexual dysfunction in women, absence
of well-validated scales, and societal ta-
boos regarding female sexuality (7,8).
Previous studies of sexual dysfunction in
womenwithdiabetesaresmallinnumber
and have signiﬁcant methodological
drawbacks, including small sample sizes
and lack of adequate characterization of
diabetes, particularly with regard to gly-
cemic control, neurovascular complica-
tions, psychological adjustment to
diabetes, and presence or absence of co-
morbid depression (6).
Nevertheless, preliminary reports
have noted a high prevalence of sexual
dysfunction in women with diabetes. In
particular, a mixed pattern of sexual
symptoms has been found, including loss
of sexual interest or desire, arousal or lu-
brication difﬁculties, painful intercourse
(dyspareunia), and loss of the ability to
reach orgasm (6). In a recent study,
women with type 1 diabetes had in-
creased rates of sexual dysfunction com-
pared with age-matched control subjects
(9). In contrast to studies in men, no as-
sociation was found between sexual dys-
function and cardiovascular, metabolic
(i.e.,glycemiccontrol,diabetesduration),
or other risk factors (i.e., age, BMI, meno-
pause, use of hormone replacement ther-
apy) (9). Another study further revealed
that sexual dysfunction in women with
diabetes is related more directly to psy-
chologicalfactors,i.e.,thepresenceofde-
pression was found to be the major
predictor of female sexual dysfunction
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tent with other studies showing depres-
sion to be a major risk and comorbid
factor of FSD (3).
To summarize, there are few data
available that have systematically evalu-
ated the effect of diabetes and/or the role
of speciﬁc diabetes therapies on female
sexual functioning. The Diabetes Control
and Complications Trial (DCCT)/
Epidemiology of Diabetes Interventions
and Complications (EDIC) study is
unique in providing the opportunity to
assess female sexual function in the con-
text of a large, multicenter, controlled
trial of long-term therapy for type 1 dia-
betes. Accordingly, this study aimed to
evaluatetheprevalence,type,riskfactors,
and predictors of FSD in a prospective
observational study examining the risk
factors associated with long-term compli-
cations of type 1 diabetes in women (11).
RESEARCH DESIGN AND
METHODS— The original cohort of
the DCCT consisted of 1,441 men and
women 13–39 years of age at study entry.
The primary prevention cohort consisted
of726subjectswithnoretinopathy,auri-
nary albumin excretion rate 40 mg/24
h, and a diabetes duration of 1–5 years.
The secondary intervention cohort con-
sisted of 715 subjects who had nonprolif-
erative retinopathy, urinary albumin
excretion rate 200 mg/24 h, and a dia-
betes duration of 1–15 years (11). They
enteredtheDCCTtrialbetween1983and
1989 and were studied for an average of
6.5 years. In total, 730 patients were ran-
domly assigned to receive conventional
diabetes treatment, and 711 were ran-
domized to receive intensive diabetes
treatment. In 1993, the DCCT was dis-
continued due to statistical evidence of a
powerful salutary effect of intensive treat-
mentonlong-termcomplications(12).At
study close-out, DCCT subjects were en-
couraged to use intensive therapy and in-
vited to join the EDIC study, a
multicenter longitudinal observational
study.Ofthe1,428survivingmembersof
the original cohort, 1,375 (95%) elected
to participate in some or all aspects of the
EDIC study (13). At EDIC year 10, 1,365
patients (713 men and 652 women) were
invited to complete self-report measures
ofsexualdysfunctionandurologicalcom-
plications (i.e., bladder dysfunction and
urinary tract infections). A total of 550
(84.4%)ofthe652womencompletedthe
Uro-EDIC questionnaire.
On the annual anniversary of enroll-
ing in the DCCT, each EDIC subject un-
derwent a standardized annual history
and physical examination, including a
detailed evaluation of overall health, di-
abetes management, occurrence of dia-
betes complications, development of
new disease, and medications used. An-
nual evaluations also include resting
electrocardiograms, Doppler ultra-
sound measurements of ankle and arm
blood pressure ratios, and arm blood
pressure. Serum creatinine and A1C are
assessed annually using the same meth-
odsasintheDCCT(12,13,14).Lipidpro-
ﬁles and 4-h urine collections for
measurement of albumin excretion rate
and creatinine clearance are obtained on
alternate years using the same methods as
in the DCCT (13). Hypertension was de-
ﬁned as systolic blood pressure 140
mmHg, diastolic blood pressure 90
mmHg, or documented use of antihyper-
tensiveagents.Hypercholesterolemiawas
deﬁned as LDL cholesterol 130 mg/dl
or use of lipid-lowering agents.
Sexual function was evaluated by an
abbreviated version of the Female Sexual
Function Index (FSFI) (15). The FSFI is a
widely used, multidimensional, well-
validated, self-report measure that as-
sessessexualfunctionacrosssixdomains,
including sexual desire, arousal, lubrica-
tion, orgasm, satisfaction, and pain
(15,16,17,18). For the present study, an
abbreviated version including 7 of the 19
original FSFI items was developed (FSFI-
R). From each of the domains of sexual
desire, arousal, lubrication, orgasm, and
pain, one item was included together with
two items from the sexual satisfaction do-
main. The items are 5-point Likert-type
items, with higher scores reﬂecting worse
sexualfunctioning.TheFSFI-Rtotalscoreis
the sum of all the items representing each
domain of sexual functioning added with
the mean score of the two items assessing
satisfaction.Thepsychometricpropertiesof
the FSFI-R were evaluated using an inde-
pendent sample of 286 women with and
245 women without sexual dysfunction se-
lected from previous validation studies
(16,17,18).Overall,theabbreviatedversion
oftheFSFIwasfoundtohaveadequatepsy-
chometric properties that are essentially
equivalenttothoseofthefull-scalemeasure
(see the online appendix available at http://
care.diabetesjournals.org/cgi/content/full/
dc08-1164/DC1).
The prevalence of a speciﬁc sexual
problem was estimated based on a do-
main-speciﬁc item analysis by combining
the percentages of women who scored in
the two lowest categories on each item
[“Almost never or never” or “A few times
(less than half the time)”], except for the
pain domain where the percentages of
women who scored in the highest catego-
ries on each item [“Almost always or al-
ways” or “Most times (more than half the
time)”] were combined. For example, the
prevalence of dyspareunia (painful inter-
course) was based on the percentage of
women who answered “most times (more
than half the time)” or “almost always or
always” to the question “How often did
youexperiencediscomfortorpainduring
vaginal penetration?”
In this study, the prevalence of de-
pression was assessed by means of a com-
posite depression variable, which was
based on study coordinator ratings of
clinical depression, based on DSM-IV cri-
teria, in addition to patient self-reports of
use of antidepressant medications and/or
psychological counseling for depressive
symptoms.
Data analysis
Initially, Pearson’s 
2 tests (Fisher’s exact
where appropriate) were used to assess
univariate associations between sexual
function scores (both total and individual
domain scores) and relevant biomedical
and psychosocial predictor variables. For
continuous measures, a nonparametric
Kruskal-Wallis test was used. Those vari-
ables that were nominally signiﬁcant at
the P  0.15 level, with respect to overall
FSD, with no adjustment for multiple
comparisons, were used in a multivariate
logistic regression model. An identical
analysis was performed using the same
covariates for each of the individual sex-
ual domains, where “FSD” is a score 2
and “no FSD” is a score 2 for each do-
main item, except for the pain domain,
where the opposite was true. FSD in the
satisfactiondomainwasindicatedbyato-
tal mean score 2. Due to the model se-
lection and the multiple testing, only
effects nominally signiﬁcant at P  0.01
are cited. Analyses were performed using
SASversion8.2(SASInstitute,Cary,NC).
RESULTS— The design, methods,
baseline ﬁndings, and main outcomes of
the DCCT and EDIC study (to date) have
beenpublishedelsewhere(11,12).Atotal
of 550 women completed the Uro-EDIC
questionnaire(responserate84.4%).This
cohort had lower triglyceride levels (P 
0.0389), had lower A1C levels (P 
0.0029),andsmokedless(P0.0060)at
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cohort of women who originally entered
the DCCT. In addition, the sample who
completed the survey did not differ on
DCCT variables at baseline compared
with the 102 women who did not partic-
ipate in the study.
In total, 116 women (21.0%) were
excluded from the analyses because they
did not provide complete data on sexual
functioning (n  10) or reported lack of
sexual activity (n  52) or absence of a
sexual partner (n  54) during the previ-
ous 12 months. At the time of the survey,
these 116 sexually inactive women dif-
feredfromthe434sexuallyactivewomen
in that they were less likely to be married
or in a partner relationship (P  0.0001),
were more often randomized to intensive
treatment (P  0.0376), had a higher
mean age (P  0.0004), were more likely
to be (post)menopausal (P  0.0415),
had a higher BMI (P  0.0271), and had
an increased prevalence of hypertension
(P  0.0011). This report thus describes
results obtained from 424 eligible partic-
ipants: 217 in the conventional and 207
in the intensive treatment groups.
Themeanageofthe424participating
womenwas42.87.1yearswithamean
duration of type 1 diabetes of 22.8  5.0
years. The majority of participants were
Caucasian (97%), were married (81%),
and had normal albumin excretion rates
(77%). Table 1 presents socioeconomic
and diabetic characteristics at DCCT
baseline and at the year 10 Uro-EDIC ex-
amination by DCCT treatment group. At
DCCT baseline, age was the only signiﬁ-
cant difference between treatment
groups; the intensive group was slightly
older (P  0.03). However, at the year 10
examination in the EDIC study, women
randomized to intensive treatment were
less likely to have retinopathy, nephrop-
athy, and peripheral neuropathy than
those randomized to conventional
treatment.
Prevalence and characteristics of
sexual dysfunction
Based on the FSFI-R cutoff score for sex-
ualdysfunctionof22.75,theoverallprev-
alence of FSD among sexually active
women in this study was found to be
35.4%. Univariate analyses revealed that
women meeting criteria for FSD were on
average older than women without FSD
(P0.0041),weremorelikelytobemar-
ried (P  0.0016), be (post)menopausal
(P  0.0019), have evidence of microvas-
culopathy (composite diabetes complica-
tions variable, P  0.0092), and be
depressed (P  0.0022) than women
without FSD (Table 2). Among those
womenwhometthecriteriaforFSD,57%
reported a problem with decreased de-
sire, 51% had problems with orgasm,
47% had inadequate lubrication, 38%
Table 1—Clinical characteristics of the female Uro-EDIC cohort (N  424)
DCCT baseline (1983–1989) Year 10 EDIC (2003)
Conventional Intensive P Conventional Intensive P
n 217 207 217 207
Sociodemographic
Age (years) 24.9  7.2 26.4  7.2 0.03 42.0  7.0 43.6  7.1 0.02
Race* 209 (96.3) 200 (96.6) 209 (96.3) 200 (96.6)
White, not of Hispanic origin 5 (2.3) 3 (1.4) 0.09* 5 (2.3) 3 (1.4) 0.09*
Black, not of Hispanic origin 0 (0.0) 4 (1.9) 0 (0.0) 4 (1.9)
Hispanic 2 (0.9) 0 (0.0) 2 (0.9) 0 (0.0)
Asian or Paciﬁc Islander 1 (0.5) 0 (0.0) 1 (0.5) 0 (0.0)
Married 94 (43.3) 98 (47.3) 0.41 167 (78.4) 168 (83.2) 0.22
Cigarette smoker† 30 (13.8) 33 (15.9) 0.54 27 (12.7) 32 (15.8) 0.37
Diabetes treatment and control
Cohort
Primary 101 (46.5) 104 (50.2) 0.45 — — 0.45
Secondary 116 (53.5) 103 (49.8) — —
Diabetes duration (years) 6.0  4.3 5.9  4.3 0.90 22.8  5.1 22.8  5.0 0.84
A1C (%) 9.1  1.6 9.1  1.5 0.85 7.8  1.2 7.9  1.4 0.67
Insulin dose (units   kg
1   day
1) 0.70  0.27 0.69  0.25 0.73 0.61  0.24 0.61  0.21 0.69
Microvascular complications
Retinopathy‡
Nonproliferative or none 217 (100.0) 207 (100.0) 0.66 123 (56.7) 165 (79.7) 0.001
Proliferative 0 (0.0) 0 (0.0) 94 (43.3) 42 (20.3)
Nephropathy
None (AER 40 mg/24 h) 209 (96.3) 195 (94.2) 0.31 153 (70.5) 174 (84.1) 0.002
Microalbuminuria (AER 40299 mg/24 h) 8 (3.7) 12 (5.8) 49 (22.6) 29 (14.0)
Albuminuria (AER 300 mg/24 h) 0 (0.0) 0 (0.0) 15 (6.9) 4 (1.9)
Hypertension§ 0 (0.0) 0 (0.0) — 61 (28.6) 57 (28.1) 0.90
Creatinine clearance ml/min per 1.73 m
2 124.8  30.0 123.7  27.9 0.86 110.0  28.0 110.8  28.0 0.66
Peripheral neuropathy 7 (3.2) 7 (3.4) 0.93 156 (71.9) 121 (58.5) 0.004
DataaremeansSDorn(%).*RaceasclassiﬁedbytheparticipantduringtheDCCTenrollmentinterview.†Deﬁnedashavingeversmoked.‡DeterminedbyETDRS
(EarlyTreatmentDiabeticRetinopathyStudy)scoreonascaleof0–23:12nonproliferative,12proliferative.§Hypertensiondeﬁnedassittingsystolicblood
pressure 140 mmHg, diastolic blood pressure 90 mmHg, or use of antihypertensive medication. Deﬁned in the DCCT by the presence of deﬁnite clinically
evident distal symmetrical polyneuropathy and an abnormal nerve conduction study or in the EDIC by the MNSI (Michigan neuropathy screening instrument): 6
positive responses on the questionnaire or a score 2 on the examination.
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21% reported pain during intercourse.
Additionally, 25% of sexually active
women reported low overall sexual satis-
faction.Forallsexualdomains,studypar-
ticipants without FSD scored higher (i.e.,
had better function) than women with
FSD (P  0.001).
FSD clinical predictors model
Univariateanalyseswereconductedtoex-
aminewhichvariablespredictedthepres-
ence or absence of sexual dysfunction in
women with type 1 diabetes (Table 2).
Those variables that were nominally sig-
niﬁcantattheP0.15level,withrespect
to FSD, with no adjustment for multiple
comparisons, were selected for further
testing in a multivariate model. The out-
come variable of “overall FSD” (based on
a cutoff score of 22.75 on the FSFI-R)
was regressed against the following pre-
dictorvariables:treatmentgroup(inten-
sive/conventional), cohort (primary/
secondary), age (adolescent vs. adult),
menopausal status, marital status, a com-
posite variable of diabetes complications,
peripheral neuropathy, clinical depres-
sion, and the log of the A1C at DCCT
eligibility. When controlling for the ef-
fects of other variables, depression status
(depressedvs.nondepressed)andmarital
status (married vs. not married) were the
only variables in the multivariate model
that were signiﬁcant predictors of FSD.
Women with type 1 diabetes in our sam-
ple who showed signs of depression were
2.08 times more likely to have FSD than
women who were not depressed (ad-
justed odds ratio [OR] 2.08 [95% Wald
CI 1.27–3.42]). Married women with
type 1 diabetes were 2.49 times more
likely to have FSD than women who were
not married (2.49 [1.34–4.65]).
Individual sexual domain analysis
In addition to the relationship with each
of the major predictor variables, the dif-
ferences between the treatment groups in
speciﬁc domains of sexual function were
both univariately and multivariately ana-
lyzed. In the univariate analyses, associa-
tions were found between menopausal
status, marital status, the composite dia-
betes complications variable, the log of
A1C at DCCT baseline, and depression
and the individual sexual domains. The
multivariate results per individual sexual
domain are summarized. Depression was
a statistically signiﬁcant risk factor for
FSD in the arousal (OR for depressed vs.
not depressed 2.47 [95% CI 1.31–4.66],
Table2—ClinicalcharacteristicsofUroEDICwomenaccordingtoFSDstatusatyear10ofthe
EDIC (N  424)*
No FSD FSD P
n 274 150
Treatment group 0.8759
Conventional 141 (51.5) 76 (50.7)
Intensive 133 (48.5) 74 (49.3)
Cohort 0.4798
Primary 129 (47.1) 76 (50.7)
Secondary 145 (52.9) 74 (49.3)
Age (years) 42.0  7.1 44.2  6.8 0.0041
Race 0.4725
Non-Caucasian 11 (4.0) 4 (2.7)
Caucasian 263 (96.0) 146 (97.3)
Diabetes duration (years) 22.7  5.0 23.0  5.1 0.4688
Married (Yes ) 205 (76.2) 130 (89.0) 0.0016
Hysterectomy (Yes)† 28 (10.2) 21 (14.0) 0.2443
Menopausal (Yes)‡ 43 (16.2) 42 (29.2) 0.0019
Retinopathy§
Nonproliferative or less 184 (67.2) 104 (69.3) 0.6456
Proliferative or greater 90 (32.8) 46 (30.7)
Nephropathy (AER) 0.8178
Normal (AER 40 mg/24 h) 212 (77.4) 115 (76.7)
Microalbuminuria (40–299 mg/24 h) 51 (18.6) 27 (18.0)
Albuminuria (AER 300 mg/24 h) 11 (4.0) 8 (5.3)
Peripheral neuropathy during the DCCT and
EDIC (Yes)
171 (62.4) 106 (70.7) 0.0876
Composite complications variable¶ 0.0092#
None 209 (76.3) 92 (61.3)
One 51 (18.6) 45 (30.0)
Two 9 (3.3) 9 (6.0)
Three 5 (1.8) 3 (2.0)
Four 0 (0.0) 1 (0.7)
Depression (Yes)** 50 (18.2) 47 (31.3) 0.0022
A1C at DCCT eligibility (%) 9.3  1.7 8.8  1.4 0.0353
A1C at EDIC year 10 (%) 7.9  1.3 7.8  1.2 0.6031
DCCT mean A1C (%) 8.2  1.4 8.1  1.5 0.3464
Time-weighted DCCT/EDIC mean A1C 8.1  1.0 8.0  1.1 0.4061
BMI (kg/m
2) 27.0  5.0 27.6  4.8 0.1912
Hypertension (Yes)†† 75 (27.8) 43 (29.5) 0.7177
Medication usage
Antihypertensives at year 10‡‡ 87 (33.6) 53 (36.8) 0.5160
Antidepressants at year 10§§ 49 (17.9) 46 (30.7) 0.0025
Data aremeans SD and n(%). Percentages are based on total sample size minus the number of missing values.
*Ten subjects did not answer the FSD question. †Hysterectomy deﬁned as a subject’s menstrual period ceasing
and it being considered permanent due to surgery. ‡Menopause deﬁned as a subject’s menstrual period ceasing
and it being considered permanent. §Determined by ETDRS (Early Treatment Diabetic Retinopathy Study) score
onascaleof0–23:12nonproliferative,12proliferative.DeﬁnedintheDCCTbythepresenceofdeﬁnite
clinically evident distal symmetrical polyneuropathy and an abnormal nerve conduction study or in the EDIC by
theMNSI(Michiganneuropathyscreeninginstrument):6positiveresponsesonthequestionnaireorascore2
ontheexamination.¶Variablehasascorebetween(0and4)dependingonthetotalnumberof“yes”responsesto
the question of ever having the following four complications: retinopathy (deﬁned as scatter laser in both eyes),
nephropathy (deﬁned as AER 300 mg/24 h, serum creatinine 2 mg/dl, and standard clearance 60 ml/min
per 1.73m
2 or dialysis and/or kidney transplant or deﬁned by the MNSI: 6 positive responses on the question-
naire and a score 2 on the examination), and cardiovascular disease (deﬁned as having any of the following six
cardiovascularevents:cardiovasculardeath,acutemyocardialinfarction,silentmyocardialinfarction,revascular-
ization, conﬁrmed angina, or cerebrovascular accident). #Fisher’s exact test. **Depression ascertained by the
study coordinator on an annual review of psychiatric events that occurred in the year(s) since the last evaluation;
if patient indicated “yes,” then the coordinator completed a documentation form to get more information (e.g.,
where treated, if medication was prescribed, DSM-III diagnosis). Additionally, if the patients indicated that they
regularlytookantidepressantsfordepressionand/orfollowedpsychologicalcounselingfordepressivesymptoms,
they were included in the depression category. ††Hypertension deﬁned as sitting systolic blood pressure 140
mmHg, diastolic blood pressure 90 mmHg, or use of antihypertensive medication. ‡‡Antihypertensive medi-
cation for any reason including use of ACE inhibitors and angiotensin II receptor blockers. §§Antidepressants
deﬁned by patient indicating regular usage of antidepressants on medication form.
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(2.41 [1.33–4.37], P  0.0041). The
complex composite variable was statisti-
callysigniﬁcantwithrespecttoFSDinthe
lubrication (for three vs. none 2.82
[0.42–18.97], two vs. none 5.332 [1.61–
17.65], and one vs. none 4.17 [2.19–
7.95], P  0.0001) and orgasm domains
(for three vs. none 3.20 [0.55–18.71],
two vs. none 3.80 [1.19–12.18], and one
vs. none 2.97 [1.62–5.45], P  0.0021).
Being married was the only signiﬁcant
risk factor for FSD in the desire domain
(for married vs. not married 2.97 [1.48–
5.93], P  0.0008). Menopause was an
important risk factor for FSD in the lubri-
cation domain (for menopausal vs. not
menopausal 2.45 [1.34–4.50], P 
0.0041).
CONCLUSIONS — Thisstudyaimed
to investigate the prevalence and risk fac-
tors associated with FSD in a large well-
characterized prospective cohort sample
of women with type 1 diabetes (Uro-
EDIC)usingavalidatedmeasureofsexual
function (FSFI-R). These ﬁndings are
based on the largest well-characterized
prospective cohort of women with type 1
diabetes in which sexual function has
beenevaluated.Consideringtherelatively
young age (mean 43 years) of the study
cohort, a prevalence rate of 35% for FSD
can be regarded as moderately high.
Giventhedecisionnottoincludesexually
inactivewomenintheanalyses,thisprev-
alence rate of 35% is rather a conservative
estimate. The FSD prevalence rate in our
study is slightly higher than those re-
portedinpreviousstudiesofwomenwith
type 1 diabetes, which ranged from 27 to
29% (12,19). The fact that in previous
studies different questionnaires were
used and that participating women were
even younger in age might (partially) ac-
count for the differences observed.
Although rates of sexual dysfunction
in women are not dissimilar to those in
men, the pattern of speciﬁc effects of dia-
betesonmenandwomenismarkedlydif-
ferent. While ED affects men both with
type 1 and with type 2 diabetes, the most
prevalent sexual dysfunction, lubrication
and sexual arousal difﬁculties, were not
the sole or the most prevalent problem in
women. Moreover, ED is strongly corre-
lated with A1C and the cardiovascular
and neuropathic complications of diabe-
tes (3,4,10). Again, in contrast, our study
reveals in a multivariate analysis that FSD
in women with type 1 diabetes is most
strongly and consistently correlated with
depression and marital status. The lack of
association between any measurement of
A1C and FSD in this study suggests that
compared with men, the sexual response
in women with diabetes is more likely to
be affected by the psychosocial aspects
(e.g., depression) than by the metabolic
control or complications of the disease.
Similar results regarding the association
between depression and FSD were ob-
served in a previous study of younger
women with type 1 diabetes (10). This
ﬁnding is also consistent with results of
other studies of sexually dysfunctional
women, in which associations have been
observed between FSD and depression
(20).Thecurrentstudythusprovidesfur-
ther evidence for the hypothesis that in
diabetic women, sexual dysfunction is
more strongly related to psychosocial as-
pects rather than the typical pattern of
cardiovascular- and metabolic-related
risk factors observed in studies of men
with diabetes (3,4,10).
Severalexplanationscanbeofferedto
account for the different pattern of effects
in men and women. It is conceivable, for
example, that these differences in sex risk
factorproﬁlesareduetodifferencesinthe
underlying physiological mechanisms
(e.g., differences in neurotransmitter in-
volvement)ofsexualresponseinmenand
women (21,22). As early as 1983, Schre-
iner-Engle (23) hypothesized that diabe-
tes-related vasculopathy or neuropathy
mightbelessreadilyperceivedbywomen
and that women with diabetes might not
be aware of a relative decreased lubrica-
tion response and therefore not likely to
report it, in contrast to men who readily
experience and report ED. Alternatively,
it has been proposed that, in general, cul-
tural and/or psychosocial factors may
play a larger role in female sexuality and
that depression is a more prevalent and
potentially more impactful factor in
women (7). Because of the multidimen-
sional etiology of FSD in women with di-
abetes, it will be necessary for future
research to use a more comprehensive as-
sessment of sexual function, including a
combinationofbothsubjective(i.e.,stan-
dardized questionnaires) and objective
methodology (i.e., vaginal plethysmogra-
phy). In this respect, we should note that
Wincze et al. (24), using vaginal plethys-
mography as an objective measure of
physiological arousal, did ﬁnd an associ-
ation between diabetes and decreased
vaginal lubrication in women. Further
studies in this area would be valuable to
test alternative hypotheses and to deter-
minewhethertreatingamooddisorderin
women with type 1 diabetes contributes
to improved sexual function independent
of glycemic control.
Finally, some limitations of the
study need to be acknowledged. Al-
thoughthisstudyisbasedonaprospec-
tive, longitudinal, observational study
oftreatmenteffectsinpatientswithtype
1 diabetes, the analyses presented are
from a cross-sectional analysis of data
obtained at 10-year follow-up. Future
studies in this ﬁeld should, therefore,
use a true longitudinal design to more
directly test sequence effects and order
ofchangesinsexualfunctionandtofur-
ther elucidate the differences observed
between the sexes. Also, since the pop-
ulation of the EDIC-study is in certain
respects limited in its diversity (age,
race, and diabetes type), the results of
this study only apply to Caucasian, rel-
atively young women with type 1 dia-
betes. Future research should attempt
to include more diverse samples in or-
dertoexaminetheriskandriskfactorof
FSD in other groups. Third, we should
reemphasize that the exclusion of sexu-
ally inactive women from our analyses
most likely biases our overall preva-
lence ﬁndings (35%) in a conservative
direction. However, by restricting our
analyses to this group of women, we are
able to ascertain speciﬁc effects on each
of the sexual function domains in rela-
tion to speciﬁc risk factors or predic-
tors. A ﬁnal limitation is that no
nondiabetic control women were in-
cluded in the study, and we therefore
relied on norms from previous clinical
studiestointerprettheprevalenceofthe
sexual dysfunctions observed. How-
ever, this is not a serious limitation in
view of the large body of published data
on sexual dysfunction in the general
population in both men and women.
Inconclusion,theresultsofthisstudy
provide further evidence that women
with type 1 diabetes are at risk for several
sexual dysfunctions. In contrast to ﬁnd-
ings in men, our results showed that in
women with type 1 diabetes, depression
and marital status are the main predictors
of FSD, whereas glycemic control and
complications were not associated with
FSD. Further studies are needed to eluci-
date the mechanisms underlying these
differences. Considering that FSD can
haveanimportantnegativeeffectonqual-
ity of life and partner relationships, the
sexualdifﬁcultiesofwomenwithdiabetes
warrant more attention in both research
Sexual dysfunction in women with type 1 diabetes
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ation of diabetes complications, women
with type 1 diabetes should also be regu-
larly queried about the presence of de-
pressive symptoms, sexual function, and
sexual satisfaction.
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